KIN1408

SKU: orb1707133

Description

KIN1408 is a small molecule RIG-I-like receptor (RLR) pathway agonist that targets MAVS to induce IRF3 nuclear translocation and subsequent innate immune gene expression. Its applications include studying antiviral responses and interferon signaling in both cellular and animal models of infection.

Research Area

Immunology & Inflammation, Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 1903800-11-2
• MW: 479.5
• Purity: 98.61%
• Formula: C₂₅H₁₉F₂N₃O₃S
• SMILES: COc1ccc2sc(NC(c3ccc(OC(F)F)cc3)c3ccc4cccnc4c3O)nc2c1
• Target: Antiviral,HCV Protease,Anti-infection
• Solubility: DMSO:30 mg/mL (62.57 mM)

Bioactivity

• In Vivo:
  Methods: MOLP-8 tumor model mice were treated with AZD-5991 (10-100 mg/kg, intravenous injection) and the efficacy of AZD-5991 on MOLP-8 tumor growth in vivo was evaluated. Results: AZD-5991 produced dose-dependent antitumor effects ranging from tumor growth inhibition (TGI) to tumor regression (TR). After ten days of treatment, AZD-5991 showed a TGI of 52% and 93% at 10 and 30 mg/kg, respectively (p < 0.0001).
• In Vitro:
  KIN1408 exhibits activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses. KIN1408 also has the ability to drive IRF3 activation to induce the expression of innate immune genes (MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells) and simultaneously inhibit dengue virus 2 RNA levels. [1-2]

Storage & Handling

• Storage: store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

KIN 1408, KIN1408, KIN-1408

Compound Identifiers

PubChem CID

119081414